Diffuse large cell lymphoma: a teaching hospital experience.
Marks
D I
DI
Department of Haematology and Medical Oncology, The Royal Melbourne Hospital.
Sheridan
W P
WP
Ellis
D W
DW
Boyd
A W
AW
Morstyn
G
G
Green
M D
MD
Fox
R M
RM
D015703:Antigens, CD; D018941:Antigens, CD19; D018951:Antigens, CD20; D000943:Antigens, Differentiation / Q000032:analysis; D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015815:Cell Adhesion Molecules; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006784:Hospitals, Teaching; D006801:Humans; D037102:Lectins; D008223:Lymphoma / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D008297:Male; D015260:Neprilysin; D011241:Prednisone / Q000627:therapeutic use; D051918:Sialic Acid Binding Ig-like Lectin 2; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D015703:Antigens, CD; D018941:Antigens, CD19; D018951:Antigens, CD20; D000943:Antigens, Differentiation; D000944:Antigens, Differentiation, B-Lymphocyte; D000951:Antigens, Neoplasm; C497867:CD22 protein, human; D015815:Cell Adhesion Molecules; D037102:Lectins; D051918:Sialic Acid Binding Ig-like Lectin 2; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D015260:Neprilysin; D011241:Prednisone